Bradykinin analogs containing the 4-amino-2-benzazepin-3-one scaffold at the C-terminus

Journal of Peptide Science

Volumn 13, Issue 3, 2007, Pages 164-170

  Ballet, S ^a   De Wachter, R ^a   Van Rompaey, K ^a   Tomboly Cs ^b   Feytens, D ^a   Toth G ^b   Quartara, L ^c   Cucchi, P ^c   Meini, S ^c   Tourwe D ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c Menarini Ricerche SpA   (Italy)

Author keywords

turn conformation; 4 amino 1,2,4,5 tetrahydro 2 benzazepin 3 ones; B2 antagonists; Bradykinin; HOE 140

Indexed keywords

BRADYKININ 1; BRADYKININ 10; BRADYKININ 2; BRADYKININ 3; BRADYKININ 4; BRADYKININ 5; BRADYKININ 6; BRADYKININ 7; BRADYKININ 8; BRADYKININ 9; BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ DERIVATIVE; ICATIBANT; INOSITOL PHOSPHATE; PHENYLALANINE DERIVATIVE; PROLINE DERIVATIVE; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RECEPTOR BINDING; DRUG STRUCTURE; INTESTINE MUSCLE; LIGAND BINDING; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RECEPTOR BLOCKING; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; BENZAZEPINES; BRADYKININ; CHO CELLS; CRICETINAE; CRICETULUS; GUINEA PIGS; HUMANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PROTEIN CONFORMATION; RECEPTOR, BRADYKININ B2;

CAVIA;

EID: 33947218318     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.827     Document Type: Article

References (32)

1. Stewart JM. Bradykinin antagonists: discovery and development. Peptides 2004; 25: 527-532.
2. Stewart JM, Gera L, York EJ, Chan DC, Bunn P. Bradykinin antagonists: Present progress and future prospects. Immunopharmacology 1999; 43: 155-161.
3. Bock MG, Longmore J. Bradykinin antagonists: new opportunities. Curr. Opin. Cherm Biol. 2000; 4: 401-406.
4. Chan D, Gera L, Helfrich B, Helm B, Stewart K, Whalley E, Bunn P. Novel bradykinin antagonist dimers for the treatment of human lung cancers. Immumopharmacology 1996; 33: 201-204.
5. Maeda H, Akaike JW, Noguchi Y, Sakata Y. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 1996; 33: 222-230.
6. Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA Jr, Taraseviciene-Stewart L. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides 2005; 28: 1288-1291.
7. Ueda H. Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol. Ther. 2006; 109: 57-77.
8. Sufka KJ, Roach JY. Stimulus properties and antinociceptive effects of selective bradykinin B1 and B2 receptor antagonists in rats. Pain 1996; 88: 99-103.
9. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides 1985; 6: 161-164.
10. Stewart JM, Vavrek RJ. Chemistry of peptide B2 bradykinin antagonists. In Bradykinin Antagonists. Basic and Clinical Research. Burch RM (ed.). Marcel Dekker: New York, 1991; 51-96.
11. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke G, Breipohl ST, KÖnig W, Schölkens BA. HOE-140, a new, long acting bradykinin antagonist: in vitro studies. Br. J. Pharmacol. 1991; 102: 769-773.
12. Wirth K, Hock FJ, Albus U, Linz W. Alpermann HG, Anagnostopoulos H, Henke S, Breipohl G, Koenig W. HOE 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol. 1991; 102: 774-777.
13. Amblard M, Daffix I, Bedos P, Bergé G, Dodey P, Paquet J-L, Luccarini J-M, Bélichard P, Pruneau D, Bellamy F, Martinez J. Synthesis and pharmacological evaluation of bradykinin analogs containing dipeptide mimics. In: Proceedings of the 25th European Peptide Symposium Bajusz S, Hudecz F (eds). Akadémiai Kiadó: Budapest, Hungary, 1998; 20-23.
14. Amblard M, Daffix I, Bedos P, Bergé G, Pruneau D, Paquet J-L, Luccarini J-M, Bélichard P, Dodey P, Martinez J. Design and synthesis of potent brady agonist Containing a Benzothiazepine moiety. J. Med. Chem. 1999; 42: 4185-4192.
15. Amblard M, Daffix I, Bergé G, Calmès M, Dodey P, Pruneau D, Paquet J-L, Luccarini J-M, Bélichard P, Martinez J. Synthesis and characterization of bradykinin B2 receptor agonists containing constrained dipeptide mimics. J. Med. Chem. 1999; 42: 4193-4201.
16. Amblard M, Raynal N, Averlant-Petit M-C, Didierjean C, Calmès M, Fabre O, Aubry A, Marraud M, Martinez J. Structural elucidation of the β-tum inducing (S)[3-amino-4-oxo-2,3-dihydro-5H-benzo[b] [1,4]thiazepin-5-yl] acetic acid (DBT) motif. Tetrahedron Lett. 2005; 46: 3733-3735.
17. Kyle DJ, Blake PR, Smithwick D, Green LM, Martin JA, Sinsko JA, Summers MF. NMR and computational evidence that high-affinity bradykinin receptor antagonists adopt C-terminal β-Turns. J. Med. Chem. 1993; 36: 1450-1460.
18. Kyle DJ, Martin JA, Burch RM, Carter JP, Lu S, Meeker S, Prosser JC, Sullivan JP, Togo J, Noronha-Blob L, Sinsko JA, Walters RF, Whaley LW, Hiner RN. Probing the bradykinin receptor: mapping the geometric topography using ethers of hydroxyproline in novel peptides. J. Med. Chem. 1991; 34: 2649-2653.
19. Kyle DJ, Martin JA, Farmer SG, Burch RM. Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med. Chem. 1991; 34:1230-1233.
20. Chacravarty S, Wilkins D, Kyle DJ. Design of potent cyclic peptide bradykinin receptor antagonists from conformationally constrained linear peptides. J. Med. Chem. 1993; 36: 2569-2571.
21. Robl JA, Simpkins LM, Sulsky R, Sieber-McMaster E, Stevenson J, Kelly YF, Sun C-Q, Misra RN, Ryono DE, Asaad MM, Bird JE, Trippodo NC, Karanewsky DS. Dual met alloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls. Bioorg. Med. Chem. Lett. 1994; 4: 1794-1800.
22. Van Rompaey K, Ballet S, Tömböly CS, De Wachter R, Vannomeslaeghe K, Biesemans M, Willem R, Tourwé D. Synthesis and evaluation of the β-tum properties of 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-ones and their spirocyclic derivative. Eur. J. Org. Chem. 2006; 2899-2911.
23. Alcaro MC, Vinci V, D'Ursi AM, Scrima M, Chelli M, Giuliani S, Meini S, Di Giacomo M, Colombo L, Papini AM. Bradykinin antagonists modified with dipeptidic mimetic β-turn inducers. Bioorg. Med. Chem. Lett. 2006; 16: 2387-2390.
24. Meini S, Cucchi P, Bellucci F, Catalani C, Faiella A, Rotondaro L, Quartara L, Giolitti A, Maggi CA. Site-directed mutagenesis at the human B2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin receptor antagonists. Biochem. Pharmacol. 2004; 67: 601-609.
25. Bellucci F, Meini S, Cucchi P. Catalani C, Reichert W, Zappitelli S, Rotondaro L, Quartara L, Giolitti A, Maggi CA. A different molecular interaction of bradykinin and the synthetic agonist FR190997 with the human B2 receptor: evidence from mutational analysis. Br. J. Pharmacol. 2003; 140: 500-506.
26. 2 receptor agonists and antagonists: a reappraisal of their pharmacology in the guinea pig ileum. Eur. J. Pharmacol. 2000; 409: 185-194.
27. Still WC, Tempczyk A, Hawley RC, Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990; 112: 6127-6129.
28. Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, Chang G, Hendrickson T, Still WC. Macromodel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Cherm. 1990; 11: 440-467.
29. Allinger NL. Yuh YH, Lii J-H. Molecular mechanics. The MM3 force field for hydrocarbons. J. Am. Chem. Soc. 1989; 111: 8551-8577.
30. 2 using the 4-amino-2-benzazepin-3-one scaffold. J. Pept. Res. 2005; 66: 222-230.
31. Tourwé D, Verschueren K, Frycia A, Davis P, Porreca F, Hruby VJ, Toth G, Jaspers H, Verheyden P, Van Binst G. Conformational restriction of Tyr and Phe side chains in opioid peptides: information about preferred and bioactive side-chain topology. Biopolymers 1995; 38: 1-12.
32. Van Rompaey K, Van den Eynde I, De Kimpe N, Tourwé D. A new versatile synthesis of 2-substituted 2-benzazepin-3-ones. Tetrahedron 2003; 59: 4421-4432.